| Literature DB >> 32942274 |
Sarah S Elsoukkary1, Maria Mostyka1, Alicia Dillard1, Diana R Berman1, Lucy X Ma1, Amy Chadburn2, Rhonda K Yantiss2, Jose Jessurun2, Surya V Seshan2, Alain C Borczuk2, Steven P Salvatore3.
Abstract
BACKGROUND: A novel coronavirus, SARS-CoV-2, was identified in Wuhan, China in late 2019. This virus rapidly spread around the world causing disease ranging from minimal symptoms to severe pneumonia, which was termed coronavirus disease (i.e., COVID). Postmortem examination is a valuable tool for studying the pathobiology of this new infection.Entities:
Keywords: Acute respiratory distress syndrome; Autopsy; COVID-19; Thrombi
Year: 2020 PMID: 32942274 PMCID: PMC7573917 DOI: 10.1159/000511325
Source DB: PubMed Journal: Pathobiology ISSN: 1015-2008 Impact factor: 4.342
Patient demographics and clinical information
| Characteristics | Patients ( |
|---|---|
| Age, years | 68 (30–100) |
| Gender | |
| Male | 22 (69%) |
| Female | 10 (31%) |
| Race | |
| White | 12 (37%) |
| Hispanic | 10 (31%) |
| Asian | 5 (16%) |
| Black | 5 (16%) |
| Site | |
| Home | 23 (72%) |
| Nursing home | 7 (22%) |
| Homeless | 2 (6%) |
| Postmortem interval, median (range), h | 43 (5–382) |
| Smoking history | |
| Never | 17 (53%) |
| Former | 8 (25%) |
| Current | 0 (0%) |
| Unknown | 7 (22%) |
| Pack-years | |
| Former | 40 (10–120) |
| SARS-CoV-2 RT-PCR | |
| Positive | 31 (97%) |
| Not tested | 1 (3%) |
| Fever, ° C | 37.8 (37–41) |
| <37.5° C | 14 (41%) |
| 37.5–38.5° C | 5 (15%) |
| >38.5° C | 9 (26%) |
| Unknown | 4 (12%) |
| Admission SpO2, % | 78 (20–99) |
| >90% | 7 (22%) |
| 90–75% | 13 (41%) |
| <75% | 7 (22%) |
| NA | 5 (15%) |
| Cough | |
| Yes | 17 (53%) |
| No | 14 (44%) |
| Unknown | 1 (3%) |
| Shortness of breath | |
| Yes | 26 (81%) |
| No | 6 (19%) |
| Anosmia | |
| Yes | 2 (6%) |
| No | 27 (84%) |
| Unknown | 3 (10%) |
| Diarrhea | |
| Yes | 1 (3%) |
| No | 29 (91%) |
| NA | 2 (6%) |
| Comorbidities | 4 (0–12) |
| None | 1 (3%) |
| ≤2 | 7 (22%) |
| 3–5 | 14 (44%) |
| >5 | 9 (28%) |
| NA | 1 (3%) |
| ICU admission | |
| Yes | 17 (53%) |
| No | 15 (47%) |
| Length of ICU stay, days | 17 (1–28) |
| Ventilator | |
| Intubated | 15 (44%) |
| NRB | 10 (29%) |
| BiPAP | 3 (9%) |
| None | 6 (18%) |
| Length of intubation, days | 17 (1–28) |
| Total duration of disease, days | 21 (1–58) |
| Treatment | |
| Antibiotics | 8 (25%) |
| Hydroxychloroquine and antibiotics | 17 (53%) |
| Hydroxychloroquine, antibiotics, and steroids | 2 (6%) |
| Supportive | 25 (78%) |
| Anti-coagulation | |
| Complications | |
| Acute kidney injury | 16 (50%) |
| Liver failure | 5 (16%) |
| Renal replacement therapy | |
| Yes | 6 (19%) |
| No | 26 (81%) |
Data are presented as n (%) and mean (range) unless otherwise stated. SpO2, oxygen saturation; NA, not available; ICU, intensive care unit; NRB, non-rebreather mask; BiPAP, bilevel positive airway pressure; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
Intubated on admission or information not available.
Comorbidities included: hypertension, hyperlipidemia, diabetes, obesity, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, asthma, obstructive sleep apnea, end stage renal disease, stroke, dementia, and cancer.
Patient laboratory data
| Parameters | Patients ( |
|---|---|
| Blood type | |
| O+ | 12 (38%) |
| A+ | 8 (25%) |
| AB+ | 2 (6%) |
| B+ | 2 (6%) |
| A– | 1 (3%) |
| NA | 7 (22%) |
| Hemoglobin, g/dL ( | 11 (5.8–15.8) |
| WBC, ×103/µL ( | 13 (0.5–43.5) |
| Lymphocytes, % ( | 13 (1–29) |
| Absolute lymphocyte count, ×103/µL ( | 2.5 (0.1–44.64) |
| Neutrophils, % ( | 77 (7–96.1) |
| Platelets, ×103/µL ( | 188 (23–400) |
| Troponin-I, ng/mL ( | 3.7 (0.01–93.85) |
| D-dimer, ng/mL ( | 4,848 (2–12,200) |
| Fibrinogen, mg/dL ( | 551 (136–1,000) |
| Lactate dehydrogenase, U/L ( | 1,071 (275–4,200) |
| Haptoglobin, mg/dL ( | 181 (6–340) |
| PT, s ( | 24 (12–80) |
| PTT, s ( | 51.6 (24.9–150) |
| Procalcitonin, ng/mL ( | 13.3 (0.06–93) |
| Erythroid sedimentation rate, mm/h ( | 74 (10–130) |
| Aspartate aminotransferase, U/L ( | 567 (18–6,000) |
| Alanine aminotransferase, U/L ( | 387 (12–4,885) |
| Alkaline phosphatase, U/L ( | 142 (53–875) |
| Total bilirubin, mg/dL ( | 1.23 (0.2–8.4) |
| Antemortem blood culture | |
| Positive | 5 (15%) |
| | 2 |
| | 1 |
| | 1 |
| Methicillin-susceptible | 1 |
| Negative | 23 (72%) |
| NA | 4 (13%) |
Data are presented as n (%) or mean (range). WBC, white blood cells; PT, prothrombin time; PTT, partial thromboplastin time.
Distribution of thrombi and parenchymal infarcts in organ systems
| Site | Thrombi ( | Thrombosis and coexisting organ infarction |
|---|---|---|
| Heart | ||
| Intramyocardial small vessel thrombi | 6 (19%) | 1 |
| Valve-associated thrombi | 2 (6%) | |
| Lungs | ||
| Small vessel thrombi | 23 (72%) | 3 |
| Large vessel thrombi | 11 (34%) | 3 |
| Both | 9 (28%) | 3 |
| Trachea | 4 (13%) | 1 |
| Thyroid | 3 (9%) | 0 |
| Lymph node | 3 (9%) | 1 |
| Bladder | 2 (6%) | 0 |
| Kidney | 2 (6%) | 1 |
| Prostate | 2 (6%) | 1 |
| Esophageal varices | 1 (3%) | 0 |
| Diaphragm | 1 (3%) | 0 |
| Ovary | 1 (3%) | 0 |
Fig. 1Multisystem microscopic thromboses were common including in the intracardiac arteries and arterioles (a, b; ×20 and ×40), highlighted by CD61 immunohistochemistry (c; ×20), in the lung with (d; ×20) or without (e; ×20) associated infarction and in other organs including the prostate (f; ×40).
Pathological characteristics of the lungs
| Characteristics | DAD | |||
|---|---|---|---|---|
| none | exudative | proliferative | both | |
| Patients | 2 (6%) | 3 (9%) | 3 (9%) | 24 (75%) |
| Alveolar neutrophils | 1 | 2 | 2 | 11 |
| Organizing pneumonia | 0 | 2 | 3 | 8 |
| Pulmonary edema | 0 | 0 | 0 | 8 |
| Combined lung weights, g | 1,630 (1,160–2,100) | 1,917 (1,830–2,020) | 2,050 (1,540–2,520) | 1,804 (1,000–3,110) |
| Duration of disease, days | 18 (1–36) | 9 (7–11) | 35 (26–42) | 20 (1–58) |
| Intubated | 0 | 0 | 2 (67%) | 13 (52%) |
| Length of intubation, days | NA | NA | 31 (28–33) | 15 (1–50) |
Data are presented as n (%) or mean (range). DAD, diffuse alveolar damage; NA, not applicable.
Reference range for combined lung weights in adults = 685–1,050 g.
Combined weight for the right lung and lung biopsy only cases are not applicable.
Clinicopathologic features of the cardiovascular system
| Features | Patients ( | Average |
|---|---|---|
| Clinical findings | ||
| Coronary artery disease | 10 (33%) | |
| Chronic heart failure | 6 (20%) | |
| Hypertension | 21 (70%) | |
| Troponin (I) | 3.7 (ng/mL) | |
| Normal | 6 (20%) | 0.027 (ng/mL) |
| Elevated | 23 (77%) | 4.89 (ng/mL) |
| Pathologic findings | ||
| Heart weight | 480 (g) | |
| Normal weight | 2 (6%) | 350 (g) |
| Cardiomegaly | 28 (93%) | 490 (g) |
| Histologic features | ||
| Atherosclerosis (>50% stenosis) | 17 (57%) | |
| Myocyte hypertrophy | 24 (80%) | |
| Myocyte ischemia | 5 (17%) | |
| Interstitial fibrosis | 20 (67%) | |
Normal troponin-I: ≤0.04 ng/mL.
Normal heart weight: male 270–360 g, female 200–280 g.
Fig. 2Liver showing steatosis and large, atypical basophilic sinusoidal structures as seen in 2 separate cases. a H&E, ×20. b PAS-D, ×20. c H&E, ×40. d PAS-D, ×40.
Fig. 3Lymph nodes with preserved architecture (a; H&E, ×20), including intact follicles highlighted by CD3 (b; IHC, ×20), CD20 (c; IHC, ×20), and CD10 (d; IHC, ×20). The subcapsular and intraparenchymal sinuses contain large transformed cells with prominent nucleoli and amphophilic cytoplasm (e, f; H&E with oil immersion, ×100), which stain for CD20 (e, inset, IHC, ×60).
Clinicopathologic features of the kidneys
| Feature | Patients ( | Notes |
|---|---|---|
| Diabetes/pre-diabetes | 20 (63%) | |
| Hypertension | 23 (72%) | |
| Obesity | 10 (31%) | |
| Acute kidney injury | 16 (53%) | |
| Requiring renal replacement therapy | 5 (17%) | |
| Creatinine, mg/dL | Range: 0.66–9.61 (n = 29) | Mean 1.7 |
| Proteinuria | 9 (50%) (n = 18) | None quantitated |
| Diabetic nephropathy | 14 (50%) | |
| Diffuse mesangial glomerulosclerosis | 11 (39%) | |
| Nodular mesangial glomerulosclerosis | 3 (11%) | |
| Other diagnoses | ||
| Obesity related glomerulopathy | 2 | |
| Papillary Necrosis | 2 | |
| Thrombotic microangiopathy | 2 | |
| Atheroembolic disease | 1 | |
| Bilateral infarction | 1 | |
| Global glomerulosclerosis | 5–95% | Mean 22.7% |
| Interstitial fibrosis and tubular atrophy | ||
| <25% | 16 (57%) | |
| 26–50% | 7 (25%) | |
| >50% | 5 (18%) | |
| Vascular sclerosis | ||
| Mild | 6 (21%) | |
| Moderate | 10 (36%) | |
| Severe | 12 (43%) | |
| C5b-9 immunohistochemical staining | ||
| Cases in arterioles | 67% | |
| Cases in glomeruli | 21% | |
Two ESRD patients excluded.
Excludes ESRD and chest only autopsies.
Fig. 4Kidney showing prominent changes of diabetic nephropathy including mesangial diabetic glomerulosclerosis and extensive arteriolar hyalinosis (a; PAS, ×40), acute tubular necrosis (b; H&E, ×20), papillary necrosis (c; H&E, ×4), atheroembolic disease (d; PAS, ×20), glomerular thrombotic microangiopathy (e; H&E, ×40), and glomerular and arteriolar endothelial staining for C5b-9 (f; IHC, ×40).